Orphazyme   Report issue

For profit Phase 3
Founded: Copenhagen Denmark (2009)
Status: Acquired by KemPharm, Inc. (2022)

Organization Overview

First Clinical Trial
2016
NCT02612129
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Orphazyme

Active Ingredients

Drugs in Phase 3 Trials (1)

arimoclomol (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Gaucher Disease (Phase 2)

Motor Neuron Disease (Phase 3)

Myositis (Phase 3)

Myositis, Inclusion Body (Phase 3)

Niemann-Pick Diseases (Phase 3)

Niemann-Pick Disease, Type A (Phase 3)

Niemann-Pick Disease, Type C (Phase 3)

Pick Disease of the Brain (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1